ZVS203e / Zhongyin Technology - LARVOL DELTA

Study on efficacy and safety of ZVS203e injection (ChiCTR) - P1/2 | N=18 | Not yet recruiting | Sponsor: Peking University Third Hospital; Peking University Third Hospital

New P1/2 trial • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation (clinicaltrials.gov) - P1/2 | N=18 | Not yet recruiting | Sponsor: Chigenovo Co., Ltd

New P1/2 trial • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Peking University Third Hospital | Not yet recruiting ➔ Recruiting | Initiation date: Jun 2023 ➔ Sep 2023

Enrollment open • Trial initiation date • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa (clinicaltrials.gov) - P1 | N=9 | Not yet recruiting | Sponsor: Peking University Third Hospital

New P1 trial • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa